Edition:
United Kingdom

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

6.71USD
16 Oct 2018
Change (% chg)

$0.45 (+7.19%)
Prev Close
$6.26
Open
$6.24
Day's High
$6.73
Day's Low
$6.24
Volume
664,360
Avg. Vol
835,193
52-wk High
$33.61
52-wk Low
$5.26

Select another date:

Mon, Oct 1 2018

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

WILMINGTON, Del Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

REFILE-UPDATE 2-Delaware judge says Fresenius can walk away from $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 Germany's Fresenius SE won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc , sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Judge rules for Fresenius in bid to end $4.8 bln Akorn deal

WILMINGTON, Del, Oct 1 A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal for U.S. drugmaker Akorn Inc and rejected Akorn's claim that the merger agreement had been breached.

Fresenius shares jump on report of win in Akorn ruling

LONDON Shares in German healthcare group Fresenius surged up 9.3 percent on Monday after a Bloomberg report that the firm won a ruling to pull out of a $4.3 billion deal to buy U.S. generic pharmaceuticals company Akorn .

Judge invokes inherent power to police mootness fees in M&A challenge

The class action watchdogs at the Competitive Enterprise Institute lost a battle this week in their challenge to a $322,500 mootness fee for shareholders' lawyers who sued over Akorn Corporation’s M&A deal with Fresenius Kabi AG. U.S. District Judge Thomas Durkin of Chicago denied a motion by CEI’s Ted Frank, an Akorn shareholder, to intervene in litigation in which Akorn agreed to pay the fee. Judge Durkin rejected CEI’s argument that Frank has an interest, as a shareholder, in assu

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion (3.6 billion pounds) takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Select another date: